2025
Sex Differences in the Safety and Efficacy of Different Durations of DAPT After PCI
Park D, Mahajan S, Fishman E, Ambrosini A, Acero L, Hu J, Campbell G, Babapour G, Kelsey M, Douglas P, Gupta A, Frampton J, Nanna M. Sex Differences in the Safety and Efficacy of Different Durations of DAPT After PCI. JACC Advances 2025, 4: 101543. PMID: 39886301, PMCID: PMC11780104, DOI: 10.1016/j.jacadv.2024.101543.Peer-Reviewed Original ResearchMonths of DAPTDuration of dual antiplatelet therapyNet adverse clinical eventsDuration of DAPTRandomized Controlled TrialsPercutaneous coronary interventionShorter duration of dual antiplatelet therapyRisk of bleedingBleeding riskLow risk of bleedingSex-based differencesAssociated with lower riskAdverse clinical eventsDual antiplatelet therapyAdverse cardiovascular eventsNetwork Meta-AnalysisWeb of Science databasesAntiplatelet therapyClinical impactCardiovascular eventsClinical eventsSystematic reviewSignificant sex-based differencesControlled TrialsCoronary intervention
2024
Impact of concomitant surgical interventions on outcomes of septal myectomy in obstructive hypertrophic cardiomyopathy
Altibi A, Sapru A, Ghanem F, Zhao Y, Alani A, Cigarroa J, Nazer B, Song H, Masri A. Impact of concomitant surgical interventions on outcomes of septal myectomy in obstructive hypertrophic cardiomyopathy. International Journal Of Cardiology 2024, 400: 131790. PMID: 38242508, DOI: 10.1016/j.ijcard.2024.131790.Peer-Reviewed Original ResearchConceptsObstructive hypertrophic cardiomyopathyMitral valve replacementCoronary Artery Bypass GraftingConcomitant surgical interventionIn-Hospital MortalitySeptal myectomyAdverse in-hospital eventsIn-hospital eventsSurgical interventionMV repairValve replacementHypertrophic cardiomyopathyOutcomes of septal myectomyAssociated with increased in-hospital mortalityOutcomes of patientsAortic valve replacementIn-Hospital Adverse EventsAdverse clinical eventsIsolated SMArtery Bypass GraftingIn-Hospital DeathNational Readmission DatabaseSymptomatic patientsMedical therapyAdverse events
2023
Coronary Intravascular Lithotripsy for Treatment of Severely Calcified Lesions: Long-Term Sex-Specific Outcomes
Frampton J, Kearney K, Abbott J, Kereiakes D, Di Mario C, Saito S, Cristea E, Riley R, Fajadet J, Shlofmitz R, Ali Z, Klein A, Price M, Hill J, Stone G, Lansky A. Coronary Intravascular Lithotripsy for Treatment of Severely Calcified Lesions: Long-Term Sex-Specific Outcomes. Journal Of The Society For Cardiovascular Angiography & Interventions 2023, 2: 101069. PMID: 39129889, PMCID: PMC11307843, DOI: 10.1016/j.jscai.2023.101069.Peer-Reviewed Original ResearchIntravascular lithotripsyLesion failureIschemia-driven target lesion revascularizationMajor adverse cardiac event ratesAdverse cardiac event ratesDrug-eluting stent placementMajor adverse cardiac eventsSmaller reference vessel diameterTarget vessel myocardial infarctionCoronary intravascular lithotripsyAdverse cardiac eventsCardiac event ratePrimary end pointTarget lesion failureTarget lesion revascularizationVessel myocardial infarctionReference vessel diameterAdverse clinical eventsHigh procedural successSex-based outcomesSex-specific outcomesLesion revascularizationAngiographic outcomesCardiac eventsCardiac deathComparative Safety Analysis of Oral Antipsychotics for In-Hospital Adverse Clinical Events in Older Adults After Major Surgery : A Nationwide Cohort Study.
Kim D, Lee S, Park C, Levin R, Metzger E, Bateman B, Ely E, Pandharipande P, Pisani M, Jones R, Marcantonio E, Inouye S. Comparative Safety Analysis of Oral Antipsychotics for In-Hospital Adverse Clinical Events in Older Adults After Major Surgery : A Nationwide Cohort Study. Annals Of Internal Medicine 2023, 176: 1153-1162. PMID: 37665998, PMCID: PMC10625498, DOI: 10.7326/m22-3021.Peer-Reviewed Original ResearchConceptsTransient ischemic attackAdverse clinical eventsHospital deathMajor surgeryClinical eventsPostoperative deliriumCohort studyOlder patientsAntipsychotic drugsArrhythmia eventsCardiac arrhythmia eventsHospital adverse clinical eventsModerate-dose treatmentPremier Healthcare DatabaseHospital adverse eventsNationwide cohort studyRetrospective cohort studyAtypical antipsychotic useOral antipsychotic drugsSignificant differencesHaloperidol useIschemic attackOral antipsychoticsAdverse eventsOral haloperidolAssociation Between Claims‐Defined Frailty and Outcomes Following 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND‐DAPT Study
Faridi K, Strom J, Kundi H, Butala N, Curtis J, Gao Q, Song Y, Zheng L, Tamez H, Shen C, Secemsky E, Yeh R. Association Between Claims‐Defined Frailty and Outcomes Following 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND‐DAPT Study. Journal Of The American Heart Association 2023, 12: e029588. PMID: 37449567, PMCID: PMC10382113, DOI: 10.1161/jaha.123.029588.Peer-Reviewed Original ResearchConceptsExtended duration dual antiplatelet therapyDuration dual antiplatelet therapyNet adverse clinical eventsDual antiplatelet therapyAdverse clinical eventsPercutaneous coronary interventionCoronary interventionClinical eventsNonfrail patientsAntiplatelet therapyFrail patientsClaims dataMonths of DAPTClaims-based indexYears of ageMajor bleedingCause mortalityMultivariable adjustmentOlder patientsDAPT studyResults PatientsBackground FrailtyMyocardial infarctionClinical trialsMedicare claims
2022
Abbreviated versus Standard Duration of DAPT after PCI: A Systematic Review and Network Meta-analysis
Park D, An S, Kumar A, Malhotra S, Jolly N, Kaur A, Kattoor A, Doukky R, Kalra A, Vij A. Abbreviated versus Standard Duration of DAPT after PCI: A Systematic Review and Network Meta-analysis. American Journal Of Cardiovascular Drugs 2022, 22: 633-645. PMID: 35781867, DOI: 10.1007/s40256-022-00541-w.Peer-Reviewed Original ResearchConceptsNet adverse clinical eventsDuration of DAPTPercutaneous coronary interventionNetwork Meta-AnalysisShorter duration of DAPTStent thrombosisMyocardial infarctionDrug-eluting stentsMeta-analysisResultsSeventeen randomized controlled trialsSystematic reviewAdverse cardiac eventsAdverse clinical eventsFrequentist network meta-analysesRisk of myocardial infarctionBackgroundDual antiplatelet therapyMonths of DAPTRandomized Controlled TrialsRandom-effects modelNetwork meta-analysesClinical presentationNo significant differenceAntiplatelet therapyMethodsThe present studyCardiac eventsClinical Impact of Residual Leaks Following Left Atrial Appendage Occlusion Insights From the NCDR LAAO Registry
Alkhouli M, Du C, Killu A, Simard T, Noseworthy PA, Friedman PA, Curtis JP, Freeman JV, Holmes DR. Clinical Impact of Residual Leaks Following Left Atrial Appendage Occlusion Insights From the NCDR LAAO Registry. JACC Clinical Electrophysiology 2022, 8: 766-778. PMID: 35387751, PMCID: PMC9233062, DOI: 10.1016/j.jacep.2022.03.001.Peer-Reviewed Original ResearchConceptsPeri-device leakAdverse eventsResidual leakMajor adverse eventsProportion of patientsAdverse clinical eventsAtrial appendage occlusionAnticoagulant utilizationMajor bleedingSystemic embolizationAppendage occlusionClinical eventsClinical impactHigher oddsHigh incidencePatientsThromboembolicSignificant differencesRegistryLarge leaksLAAOLeakHigher proportionDaysAnticoagulation
2021
Determinants and Outcomes Associated With Urinary Calcium Excretion in Chronic Kidney Disease
Liu J, Tio M, Verma A, Schmidt I, Ilori T, Knauf F, Mc Causland F, Waikar S. Determinants and Outcomes Associated With Urinary Calcium Excretion in Chronic Kidney Disease. The Journal Of Clinical Endocrinology & Metabolism 2021, 107: e281-e292. PMID: 34390334, PMCID: PMC8684460, DOI: 10.1210/clinem/dgab574.Peer-Reviewed Original ResearchConceptsUrinary calcium excretionChronic kidney diseaseEnd-stage kidney diseaseCalcium excretionKidney diseaseChronic Renal Insufficiency Cohort (CRIC) StudyIncident end-stage kidney diseaseLevel of CKDSelf-identified black raceAtherosclerotic cardiovascular disease eventsSerum parathyroid hormoneCardiovascular disease eventsAdverse clinical eventsAdverse clinical outcomesStage kidney diseaseBaseline eGFRCKD progressionUrinary sodiumCause mortalityCohort studyLoop diureticsThiazide diureticsClinical outcomesParathyroid hormoneVascular calcification
2020
Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
You SC, Rho Y, Bikdeli B, Kim J, Siapos A, Weaver J, Londhe A, Cho J, Park J, Schuemie M, Suchard MA, Madigan D, Hripcsak G, Gupta A, Reich CG, Ryan PB, Park RW, Krumholz HM. Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. JAMA 2020, 324: 1640-1650. PMID: 33107944, PMCID: PMC7592033, DOI: 10.1001/jama.2020.16167.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAdultAgedAged, 80 and overAlgorithmsAspirinCase-Control StudiesCause of DeathClopidogrelDatabases, FactualDyspneaFemaleHemorrhageHumansIschemiaMaleMiddle AgedMyocardial InfarctionNetwork Meta-AnalysisPercutaneous Coronary InterventionPropensity ScorePurinergic P2Y Receptor AntagonistsRecurrenceRepublic of KoreaRetrospective StudiesStrokeTicagrelorUnited StatesConceptsNet adverse clinical eventsAcute coronary syndromePercutaneous coronary interventionAdverse clinical eventsHemorrhagic eventsIschemic eventsHazard ratioCause mortalityCoronary syndromeCoronary interventionClinical eventsRisk of NACEClinical practiceLarge randomized clinical trialsPrimary end pointRetrospective cohort studyPropensity-matched pairsSummary hazard ratioRandomized clinical trialsRoutine clinical practiceSignificant differencesP2Y12 platelet inhibitorsTicagrelor groupCohort studySecondary outcomesImplications of Abnormal Exercise Electrocardiography With Normal Stress Echocardiography
Daubert MA, Sivak J, Dunning A, Douglas PS, Coyne B, Wang TY, Mark DB, Velazquez EJ. Implications of Abnormal Exercise Electrocardiography With Normal Stress Echocardiography. JAMA Internal Medicine 2020, 180: 494-502. PMID: 31985749, PMCID: PMC6990669, DOI: 10.1001/jamainternmed.2019.6958.Peer-Reviewed Original ResearchConceptsNormal stress echocardiographyComposite end pointStress echoExercise electrocardiographyStress echocardiographyMyocardial infarctionDownstream testingEnd pointDuke University Medical CenterExercise stress echoNegative exercise ECGStress ECG findingsAdverse cardiac eventsIncremental prognostic valueObservational cohort studyAdverse clinical eventsCoronary artery diseaseIndividual adverse eventsPopulation of patientsUniversity Medical CenterImaging resultsCoronary revascularizationAdverse eventsCardiac eventsCohort studyDefining device success for percutaneous coronary intervention trials: a position statement from the European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology.
Chang CC, Kogame N, Onuma Y, Byrne RA, Capodanno D, Windecker S, Morel MA, Cutlip DE, Krucoff MW, Stone GW, Lansky AJ, Mehran R, Spitzer E, Fraser AG, Baumbach A, Serruys PW. Defining device success for percutaneous coronary intervention trials: a position statement from the European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology. EuroIntervention 2020, 15: 1190-1198. PMID: 31475907, DOI: 10.4244/eij-d-19-00552.Peer-Reviewed Original ResearchConceptsDevice success rateDrug-eluting stentsPercutaneous coronary intervention trialsCoronary intervention trialsDevice successIntervention trialsClinical trialsSuccess rateSymptomatic coronary artery diseasePercutaneous coronary interventionAdverse clinical eventsCoronary artery diseasePercutaneous Cardiovascular InterventionsDifferent trialsRevascularisation proceduresCoronary interventionAngiographic outcomesArtery diseaseClinical eventsComparative trialsEndpoint definitionsDrug AdministrationCardiovascular interventionsPerformance endpointEuropean Association
2018
Acute Myocardial Infarction Outcomes in Systemic Lupus Erythematosus (from the Nationwide Inpatient Sample)
Ando T, Adegbala O, Akintoye E, Ashraf S, Briasoulis A, Takagi H, Afonso L. Acute Myocardial Infarction Outcomes in Systemic Lupus Erythematosus (from the Nationwide Inpatient Sample). The American Journal Of Cardiology 2018, 123: 227-232. PMID: 30424870, DOI: 10.1016/j.amjcard.2018.09.043.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionSystemic lupus erythematosusPropensity-matched cohortMajor adverse eventsHospital mortalityTherapy ratesRevascularization strategyNSTEMI admissionsHospital outcomesAdverse eventsLupus erythematosusMyocardial infarctionOdds ratioAcute myocardial infarction (AMI) outcomesMajor adverse clinical eventsCoronary artery bypass surgeryMyocardial infarction outcomesNon-SLE cohortAcute coronary syndromeArtery bypass surgeryNationwide inpatient databaseAdverse clinical eventsElevation myocardial infarctionPercutaneous coronary interventionAcute myocardial infarction
2017
Admission Glucose and In-hospital Mortality after Acute Myocardial Infarction in Patients with or without Diabetes: A Cross-sectional Study
Zhao S, Murugiah K, Li N, Li X, Xu ZH, Li J, Cheng C, Mao H, Downing NS, Krumholz HM, Jiang LX. Admission Glucose and In-hospital Mortality after Acute Myocardial Infarction in Patients with or without Diabetes: A Cross-sectional Study. Chinese Medical Journal 2017, 130: 767-775. PMID: 28345539, PMCID: PMC5381309, DOI: 10.4103/0366-6999.202733.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionAbsence of diabetesAdverse clinical eventsAdmission glucoseNondiabetic patientsClinical eventsPrognostic valueBlood glucoseMyocardial infarctionRepresentative sampleGlucose levelsPatientsAdmissionMortalityGlucosePrior studiesHyperglycemiaInfarctionDiabetesMixed resultsStatistical power
2015
Prognostic utility of myocardial blush grade after PCI in patients with NSTE‐ACS: Analysis from the ACUITY trial
Ng VG, Lansky AJ, Toro S, Parise H, Cristea E, Mehran R, Stone GW. Prognostic utility of myocardial blush grade after PCI in patients with NSTE‐ACS: Analysis from the ACUITY trial. Catheterization And Cardiovascular Interventions 2015, 88: 215-224. PMID: 25641255, DOI: 10.1002/ccd.25865.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedChi-Square DistributionCoronary AngiographyCoronary CirculationCoronary VesselsFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisMyocardial Perfusion ImagingNon-ST Elevated Myocardial InfarctionOdds RatioPercutaneous Coronary InterventionPredictive Value of TestsProportional Hazards ModelsRisk AssessmentRisk FactorsTreatment OutcomeConceptsMyocardial blush gradePercutaneous coronary interventionST-segment elevation myocardial infarctionNSTE-ACS patientsComposite ischemiaMBG 0/1Non-ST segment elevation acute coronary syndromesSegment elevation acute coronary syndromesElevation acute coronary syndromeFinal myocardial blush gradeIndependent angiographic core laboratoryNet adverse clinical eventsNon-CABG major bleedingNormal epicardial flowOutcomes of patientsTIMI 3 flowAcute coronary syndromeIschemia-driven revascularizationAdverse clinical eventsElevation myocardial infarctionNormal myocardial perfusionAngiographic core laboratoryHigh rateACUITY trialMajor bleedingMetallic Limus‐Eluting Stents Abluminally Coated with Biodegradable Polymers: Angiographic and Clinical Comparison of a Novel Ultra‐Thin Sirolimus Stent Versus Biolimus Stent in the DESTINY Randomized Trial
Lemos P, Abizaid A, Meireles G, Sarmento-Leite R, Prudente M, Cantarelli M, Dourado A, Mariani J, Perin M, Costantini C, Costa R, Costa J, Chamie D, Campos C, Ribeiro E. Metallic Limus‐Eluting Stents Abluminally Coated with Biodegradable Polymers: Angiographic and Clinical Comparison of a Novel Ultra‐Thin Sirolimus Stent Versus Biolimus Stent in the DESTINY Randomized Trial. Cardiovascular Therapeutics 2015, 33: 367-371. PMID: 26352896, DOI: 10.1111/1755-5922.12159.Peer-Reviewed Original ResearchMeSH KeywordsAbsorbable ImplantsAgedBrazilCardiovascular AgentsCoated Materials, BiocompatibleCoronary AngiographyCoronary Artery DiseaseCoronary RestenosisCoronary ThrombosisCoronary VesselsDrug-Eluting StentsFemaleHumansMaleMiddle AgedMyocardial InfarctionPercutaneous Coronary InterventionPredictive Value of TestsProspective StudiesProsthesis DesignSirolimusTime FactorsTreatment OutcomeConceptsSirolimus-eluting stentsLate lumen lossRandomized trialsPrimary endpointLow dose of sirolimusLumen lossIn-stent late lumen lossBiolimus-eluting stentDose of sirolimusAngiographic in-stent late lumen lossOutcomes of patientsAdverse clinical eventsAngiographic late lumen lossDrug-eluting stent formulationsLimus-eluting stentsIncidence of deathClinical eventsClinical comparisonLow dosesStent thrombosisMyocardial infarctionStudy populationStentPatientsTrials
2014
Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis
Ahmadian A, Brogan A, Berman J, Sverdlov AL, Mercier G, Mazzini M, Govender P, Ruberg FL, Miller EJ. Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis. Journal Of Nuclear Cardiology 2014, 21: 925-939. PMID: 24879453, DOI: 10.1007/s12350-014-9901-9.Peer-Reviewed Original ResearchMeSH KeywordsFemaleFluorodeoxyglucose F18Heart DiseasesHumansImage EnhancementImage Interpretation, Computer-AssistedMaleMiddle AgedMultimodal ImagingMyocardial Perfusion ImagingPositron-Emission TomographyRadiopharmaceuticalsReproducibility of ResultsRetrospective StudiesSarcoidosisSensitivity and SpecificityTomography, X-Ray ComputedConceptsFDG PET/CTPET/CTCardiac sarcoidosisStandardized uptake valueMyocardial perfusion imagingClinical eventsPerfusion imagingCardiac FDG PET/CTAdverse clinical eventsOnly independent predictorNegative control studyCS correlatesImmunosuppressive treatmentPrednisone treatmentImmunosuppression treatmentIndependent predictorsFDG uptakeOncologic indicationsPerfusion defectsNegative studiesRepeat examinationLow EFUptake valueControl studyMultivariate analysis
2013
Comparative effectiveness of upstream glycoprotein IIb/IIIa inhibitors in patients with moderate- and high-risk acute coronary syndromes: An Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) substudy
Nazif T, Mehran R, Lee E, Fahy M, Parise H, Stone G, Kirtane A. Comparative effectiveness of upstream glycoprotein IIb/IIIa inhibitors in patients with moderate- and high-risk acute coronary syndromes: An Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) substudy. American Heart Journal 2013, 167: 43-50. PMID: 24332141, DOI: 10.1016/j.ahj.2013.10.013.Peer-Reviewed Original ResearchConceptsGlycoprotein IIb/IIIa receptor inhibitorsNet adverse clinical eventsMajor adverse cardiac eventsHigh-risk acute coronary syndromesAcute coronary syndromeMajor bleedingCoronary syndromeComposite major adverse cardiac eventsIIb/IIIa receptor inhibitorsGlycoprotein IIb/IIIa inhibitorsEarly invasive management strategyIIb/IIIa inhibitorsInvasive management strategySafety of tirofibanAdverse cardiac eventsSimilar clinical outcomesAdverse clinical eventsUse of tirofibanComparative effectiveness analysisSignificant differencesACUITY trialAcute CatheterizationUpstream tirofibanMultivariable adjustmentUpstream therapyThe prognostic importance of left ventricular function in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial
Ng VG, Lansky AJ, Meller S, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie B, Shah R, Mehran R, Stone GW. The prognostic importance of left ventricular function in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial. European Heart Journal Acute Cardiovascular Care 2013, 3: 67-77. PMID: 24562805, PMCID: PMC3932775, DOI: 10.1177/2048872613507149.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntithrombinsCoronary AngiographyDrug-Eluting StentsElectrocardiographyFemaleFollow-Up StudiesGated Blood-Pool ImagingHirudinsHumansMaleMiddle AgedMyocardial InfarctionPeptide FragmentsPercutaneous Coronary InterventionPrognosisProspective StudiesRecombinant ProteinsTreatment OutcomeVentricular Function, LeftConceptsST-segment elevation myocardial infarctionLeft ventricular ejection fractionPaclitaxel-eluting stentsHORIZONS-AMI trialElevation myocardial infarctionLV dysfunctionLV functionMyocardial infarctionIschaemia-driven target lesion revascularizationMajor adverse cardiovascular eventsNet adverse clinical eventsPrimary percutaneous coronary interventionBaseline LV dysfunctionIndex revascularization procedureAdverse cardiovascular eventsOutcomes of patientsTarget lesion revascularizationHigh-risk patientsSubstantial clinical benefitAdverse clinical eventsNormal LV functionPercutaneous coronary interventionVentricular ejection fractionLeft ventricular functionBare metal stentsA Pilot Study of an mHealth Application for Healthcare Workers: Poor Uptake Despite High Reported Acceptability at a Rural South African Community-Based MDR-TB Treatment Program
Chaiyachati KH, Loveday M, Lorenz S, Lesh N, Larkan LM, Cinti S, Friedland GH, Haberer JE. A Pilot Study of an mHealth Application for Healthcare Workers: Poor Uptake Despite High Reported Acceptability at a Rural South African Community-Based MDR-TB Treatment Program. PLOS ONE 2013, 8: e64662. PMID: 23724075, PMCID: PMC3665589, DOI: 10.1371/journal.pone.0064662.Peer-Reviewed Original ResearchConceptsAdverse event formsMDR-TB patientsMDR-TB therapyHealthcare workersMobile healthcare workersMDR-TB treatment programmeMultidrug-resistant tuberculosis epidemicPoor uptakeAdverse clinical eventsResource-poor settingsRural South African communityEvent formsMixed-methods evaluationClinical eventsSpecialty centersCommunity hospitalHCWs' perceptionsTuberculosis epidemicOwn careIntensive phaseHealth professionalsHealth interventionsPoor settingsTreatment programQualitative focus groups
2012
Long-Term Prognosis of Patients Presenting With ST-Segment Elevation Myocardial Infarction With No Significant Coronary Artery Disease (from The HORIZONS-AMI Trial)
Larsen AI, Nilsen DW, Yu J, Mehran R, Nikolsky E, Lansky AJ, Caixeta A, Parise H, Fahy M, Cristea E, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Stone GW. Long-Term Prognosis of Patients Presenting With ST-Segment Elevation Myocardial Infarction With No Significant Coronary Artery Disease (from The HORIZONS-AMI Trial). The American Journal Of Cardiology 2012, 111: 643-648. PMID: 23261001, DOI: 10.1016/j.amjcard.2012.11.011.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionSignificant coronary artery diseaseCoronary artery diseaseElevation myocardial infarctionArtery diseaseMyocardial infarctionGreater left ventricular ejection fractionMajor adverse cardiovascular eventsNet adverse clinical eventsAcute Myocardial Infarction trialObstructive coronary artery diseaseLeft ventricular ejection fractionLower body mass indexBaseline coronary angiogramAdverse cardiovascular eventsCoronary artery bypassMyocardial Infarction trialNormal coronary arteriesOutcomes of patientsAdverse clinical eventsPrognosis of patientsVentricular ejection fractionBody mass indexQuantitative coronary angiographyRate of death
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply